Palivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (RSV)
about
Transmission of surfactant protein variants and haplotypes in children hospitalized with respiratory syncytial virus.Costs of hospitalization with respiratory syncytial virus illness among children aged <5 years and the financial impact on households in Bangladesh, 2010.Antiviral Activity of TMC353121, a Respiratory Syncytial Virus (RSV) Fusion Inhibitor, in a Non-Human Primate ModelSerious Adverse Events in the Canadian Registry of Children Receiving Palivizumab (CARESS) for Respiratory Syncytial Virus PreventionImmunological considerations for developing antibody therapeutics for Influenza A.Characterization of Pre-F-GCN4t, a Modified Human Respiratory Syncytial Virus Fusion Protein Stabilized in a Noncleaved Prefusion Conformation.
P2860
Palivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (RSV)
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Palivizumab: a review of its u ...... piratory syncytial virus (RSV)
@en
Palivizumab: a review of its u ...... st respiratory syncytial virus
@nl
type
label
Palivizumab: a review of its u ...... piratory syncytial virus (RSV)
@en
Palivizumab: a review of its u ...... st respiratory syncytial virus
@nl
prefLabel
Palivizumab: a review of its u ...... piratory syncytial virus (RSV)
@en
Palivizumab: a review of its u ...... st respiratory syncytial virus
@nl
P2093
P2860
P1476
Palivizumab: a review of its u ...... piratory syncytial virus (RSV)
@en
P2093
Gretchen L Brummel
Joseph M Geskey
Neal J Thomas
P2860
P577
2007-03-01T00:00:00Z